Dipyridamole may induce migraine in patients with migraine without aura

Cephalalgia

Volumn 26, Issue 8, 2006, Pages 925-933

  Kruuse, C ^a   Lassen, L H ^a   Iversen, H K ^a   Oestergaard, S ^a   Olesen, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Blood flow velocity; Dipyridamole; Headache; Migraine; Phosphodiesterase inhibitor

Indexed keywords

DIPYRIDAMOLE; IBUPROFEN; PARACETAMOL; SUMATRIPTAN;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; BLOOD PRESSURE MEASUREMENT; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FLUSHING; HEADACHE; HEART RATE; HUMAN; MALE; MIDDLE CEREBRAL ARTERY; MIGRAINE; PAIN ASSESSMENT; PHOTOPHOBIA; RATING SCALE; SIDE EFFECT; SINGLE BLIND PROCEDURE; TACHYCARDIA;

ADMINISTRATION, ORAL; ADULT; DIPYRIDAMOLE; FEMALE; HEADACHE DISORDERS, SECONDARY; HUMANS; MALE; MIDDLE AGED; MIGRAINE WITHOUT AURA; RISK ASSESSMENT; RISK FACTORS; SINGLE-BLIND METHOD; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33746101875     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2006.01137.x     Document Type: Article

References (34)

1. Sivenius J, Cunha L, Diener HC, Forbes C, Laakso M, Lowenthal A et al. Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group. Acta Neurol Scand 1999; 99:54-60.
2. Dal Porto R, Faletra F, Picano E, Pirelli S, Moreo A, Varga A. Safety, feasibility, and diagnostic accuracy of accelerated high-dose dipyridamole stress echocardiography. Am J Cardiol 2001; 87:520-4.
3. FitzGerald GA. Dipyridamole. N Engl J Med 1987; 316:1247-57.
4. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995; 75:725-48.
5. European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 1997; 151 (Suppl.):S1-77.
6. Meyers AM, Topham L, Ballow J, Totah D, Wilke R. Adverse reactions to dipyridamole in patients undergoing stress/rest cardiac perfusion testing. J Nucl Med Technol 2002; 30:21-4.
7. Roman MR, Angelides S, Freeman AP, Parker MK, da Silva I. The safety of dipyridamole in patients undergoing myocardial perfusion scintigraphy prior to lung volume reduction surgery. Eur J Nucl Med 2001; 28:1405-8.
8. Kruuse C, Jacobsen TB, Lassen LH, Thomsen LL, Hasselbalch SG, Dige-Petersen H et al. Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects. J Cereb Blood Flow Metab 2000; 20:1372-9.
9. Kruuse C, Thomsen LL, Jacobsen TB, Olesen J. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab 2002; 22:1124-31.
10. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003; 126:241-7.
11. Birk S, Petersen K, Kruuse C, Guieu R, Jonassen O, Eisert W et al. The effect of circulating adenosine on cerebral hemodynamics and headache generation in healthy subjects. Cephalalgia 2005; 25:369-77.
12. Iversen HK, Olesen J, Tfelt Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38:17-24.
13. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1994; 1:73-80.
14. Bjornsson TD, Mahony C. Clinical pharmacokinetics of dipyridamole. Thromb Res Suppl 1983; 4:93-104.
15. Thomsen LL, Iversen HK, Brinck TA, Olesen J. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia 1993; 13:395-9.
16. Thomsen LL, Iversen HK. Experimental and biological variation of three-dimensional transcranial Doppler measurements. J Appl Physiol 1993; 75:2805-10.
17. Shirahata N, Henriksen L, Vorstrup S, Holm S, Lauritzen M, Paulson OB et al. Regional cerebral blood flow assessed by 133Xe inhalation and emission tomography: normal values. J Comput Assist Tomogr 1985; 9:861-6.
18. Ito H, Kinoshita T, Tamura Y, Yokoyama I, Iida H. Effect of intravenous dipyridamole on cerebral blood flow in humans. A PET study. Stroke 1999; 30:1616-20.
19. Hawkes CH. Dipyridamole in migraine. Lancet 1978; 2 (8081):153.
20. Parfenova H, Shibata M, Zuckerman S, Mirro R, Leffler CW. Cyclic nucleotides and cerebrovascular tone in newborn pigs. Am J Physiol 1993; 265 (6 Part 2):H1972-H1982.
21. Kruuse C, Rybalkin SD, Khurana TS, Jansen-Olesen I, Olesen J, Edvinsson L. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. Eur J Pharmacol 2001; 420:55-65.
22. Guideri F, Capecchi PL, Lazzerini PE, Pasini FL. Effects of dipyridamole and adenosine on vasoactive peptides calcitonin gene-related peptide and atrial natriuretic peptide in humans: role of sympathetic activation. Clin Exp Pharmacol Physiol 2000; 27:676-9.
23. Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54-61.
24. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 1993; 4:1027-30.
25. Lassen LH, Ashina M, Christiansen I, Olesen J. Nitric oxide syntethase inhibition in migraine. Lancet 1997; 349:401-2.
26. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28:183-7.
27. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104-10.
28. Guieu R, Devaux C, Henry H, Bechis G, Pouget J, Mallet D et al. Adenosine and migraine. Can J Neurol Sci 1998; 25: 55-8.
29. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000; 20:907-18.
30. Newman EA. Glial cell inhibition of neurons by release of ATP. J Neurosci 2003; 23:1659-66.
31. Humphrey PP, Bland-Ward PA, Carruthers AM, Connor HE, Feniuk W, Honey AC et al. Inhibition of trigeminal nociceptive afferents by adenosine A1 receptor activation: a novel approach towards the design of new anti-migraine compounds. Cephalalgia 2001; 21:268-9.
32. Birk S, Kruuse C, Petersen K, Jonassen O, Tfelt-Hansen P, Olesen J. Cilostazol causes headache in healthy volunteers; evidence for invlovement of cAMP? Cephalalgia 2003; 7:657 (Abstract).
33. Giffin NJ, Kowacs F, Libri V, Williams P, Goadsby PJ, Kaube H. Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 2003; 23:287-92.
34. Goadsby PJ. Can we develop neurally acting drugs for the treatment of migraine? Nat Rev Drug Discov 2005; 4:741-50.